Aging is a multifaceted biological process that results in a gradual decline in physiological function, significantly impacting health and increasing susceptibility to various diseases. Common aging-related diseases include cardiovascular disease, diabetes, neurodegenerative disorders, and certain types of cancer. These diseases reduce the quality of life and impose a substantial burden on healthcare systems worldwide. Given the increasing life expectancy, developing effective anti-aging drugs is essential to mitigate these health risks, promote longevity, and improve the overall well-being of the aging population..
Caloric restriction (CR), a dietary intervention involving a reduction in caloric intake without malnutrition, has been extensively studied as one of the most effective methods to promote longevity and healthspan across various species. Therefore, developing calorie restriction mimetics (CRMs) has emerged as a promising alternative. Recent advances in the field have highlighted the feasibility and significance of developing CRMs. For instance, conventional CRMs like rapamycin, metformin, and spermidine, and new CRMs such as fungal polysaccharides, inorganic nitrate, and trientine, have shown potential in mimicking the molecular, cellular, and physiological effects of CR.
Additionally, lithocholic acid (LCA) has been shown to mimic the effects of caloric restriction. Since LCA can be derived from natural sources or synthesized, its availability and relatively low cost compared to many CRMs make it an attractive option for both research and clinical applications. However, it is important to note that, as of now, no caloric restriction mimetics specifically based on LCA are available on the market. This presents both a challenge and an opportunity for research and development..
CD BioSciences is developing new drugs to promote healthy aging. As a natural bile acid, LCA is generally considered to be safe and cost-effective. Based on LCA, we are currently developing a novel CRM named CB-LCA-001.
| Project | Target | Discovery | Preclinical | Phase I |
| CB-LCA-001 | TULP3 |
TULP3 (Tubby Like Protein 3) is a protein that plays a significant role in cellular signaling pathways related to metabolism and energy homeostasis. It has been reported that LCA can influence aging processes by binding to TULP3.
Drug Modality
CB-LCA-001, a novel small molecule drug based on LCA, has favorable pharmacokinetic properties, allowing for easy oral administration, improved bioavailability, and convenience for long-term use.
If you are interested in our anti-aging drug projects, please feel free to contact us or make an online inquiry.
Reference
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
CD BioScience is a research service provider focused on aging research, specializing in providing research on aging mechanisms, preclinical drug discovery and development, and the development of healthcare and skincare products.
Copyright © 2025 CD BioSciences. All rights reserved.